Comparative Pharmacology
Head-to-head clinical analysis: MIDOZALAM HYDROCHLORIDE versus TEMAZEPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIDOZALAM HYDROCHLORIDE versus TEMAZEPAM.
MIDOZALAM HYDROCHLORIDE vs TEMAZEPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Midazolam hydrochloride is a benzodiazepine that enhances the effect of the neurotransmitter gamma-aminobutyric acid (GABA) at the GABA-A receptor, resulting in increased chloride ion conductance, neuronal hyperpolarization, and inhibition of neuronal transmission. This produces sedative, anxiolytic, amnestic, and anticonvulsant effects.
Positive allosteric modulator of GABA-A receptors, enhancing the effect of GABA by increasing chloride ion influx, leading to neuronal hyperpolarization and sedation.
2.5-10 mg IV bolus for induction; 0.05-0.2 mg/kg/h IV infusion for sedation. IM: 0.07-0.08 mg/kg (max 5 mg) 30-60 min pre-procedure.
10-20 mg orally at bedtime, up to 30 mg in severe insomnia.
None Documented
None Documented
Clinical Note
moderateTemazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Temazepam is combined with Fluticasone propionate."
Clinical Note
moderateTemazepam + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Temazepam."
Clinical Note
moderateTemazepam + Haloperidol
"The risk or severity of adverse effects can be increased when Temazepam is combined with Haloperidol."
Clinical Note
moderateTemazepam + Sulfisoxazole
Terminal elimination half-life: 1.5-3 hours in healthy adults; prolonged in elderly (up to 6 hours), obesity, hepatic cirrhosis (up to 20 hours), and congestive heart failure.
Terminal elimination half-life is 8–20 hours in healthy adults (mean ~15 hours); may be prolonged in elderly (up to 50 hours) and in hepatic impairment (up to 40 hours); clinical context: typical dosing interval is 12–24 hours.
Renal excretion of metabolites (approximately 90% as glucuronide conjugates, with less than 1% unchanged drug) and biliary/fecal excretion (approximately 5-10%).
Renal excretion of conjugated metabolites (primarily as glucuronide) accounts for approximately 80% of an oral dose; fecal excretion accounts for about 12%; less than 1% is excreted unchanged in urine.
Category C
Category D/X
Benzodiazepine
Benzodiazepine
"The metabolism of Sulfisoxazole can be decreased when combined with Temazepam."